AFU Oncology Committee
French recommendations of the AFU Oncology Committee for Bladder Cancer: Update 2025
Abstract
The Oncology Committee of the French Urology Association (CCAFU) is proposing a 2025 summary of recommendations' changes for the management of bladder cancer (BCa).
A systematic review of the literature from July 2024 to September 2025 was conducted by the CCAFU on the evolutions of diagnostic and therapeutic management of BCa evaluating the newly published references with their level of evidence.
On NMIBC BCa guidelines: the addition of a new recommendation to the sections "4.3. High-risk tumours" and "5.2. BCG-endovesical therapy" related to the association BCG + systemic immunotherapy. On MIBC guidelines: new recommendations to the sections "3.1.1. Neoadjuvant cisplatin-based chemotherapy" and "3.2.2. Adjuvant immunotherapy treatment" related to the perioperative combination of chemotherapy and immunotherapy.
This 2025 summary of changes of French recommendations should help physicians to stay up-to-date with recent evolutions and aim to improve the management of BCa patients.
Source and rights
Published by The French journal of urology, 2025. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- AFU Oncology Committee
- Published
- 2025
- Applies to
- 🇫🇷 France
- Scope
- National
- Journal
- The French journal of urology
More in oncology
- Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyNational Comprehensive Cancer Network · 2026
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance) [2] · 2026
